Personalized Search
Displaying 1 - 20 of 20
-
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15. His father, Benjamin, developed kidney cancer when Stone was just 5 years old, and 10 years later, the disease...Article last updated May 30, 2023.Node ID (debugging only): 9935
-
This is the first episode of our new podcast. Leigh Clark, Patient Educator, describes the bone marrow failure journey and how AAMDSIF can help!Podcast Episode last updated November 2, 2022.Node ID (debugging only): 8157
-
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines in patients with solid cancers, such as lung, breast, or prostate cancer. November 2021 – Lung Cancer Laura Morgan The...Article last updated January 24, 2022.Node ID (debugging only): 9849
-
Subscribers to the GVHD Interactive Provider Network mailing list receive: Updates about events and trainings Login information to participate in the online discussions Access to the ECHO platform Subscribers may opt out and unsubscribe at any time. Please find the required and optional fields below.Webform last updated April 12, 2024.Node ID (debugging only): 9953
-
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure diseases. If you are a patient: please fill out the form below and a complete information packet will be mailed to you free of charge. Alternatively you can...Webform last updated April 12, 2024.Node ID (debugging only): 8326
-
AAMDSIF receives support from corporate partners who invest in advancing our mission. Thanks to their financial contributions, we are able to provide answers, support, and hope to patients, their families, and healthcare professionals entrusted with providing quality care. AAMDSIF Corporate Partners provide financial and in-kind support of programming through sponsorships and grants. AAMDSIF...Page last updated April 4, 2024.Node ID (debugging only): 10356
-
Deferiprone is in a class of medications called iron chelators. It works by attaching to iron in the body so that it can be excreted (removed from the body). Deferiprone comes in a pill form and is taken by mouth. Deferiprone is approved for use in Europe. Researchers in the U.S. are studying deferiprone for treating iron overload in patients with thalassemia. Deferiprone binds with iron in the...Drug last updated April 4, 2024.Node ID (debugging only): 4424
-
The U.S. Food and Drug Administration (FDA) approved fludarabine for treating chronic lymphocytic leukemia (CCL). Researchers are studying fludarabine in combination with other medicines for treating bone marrow failure.Drug last updated April 4, 2024.Node ID (debugging only): 4428
-
It is known as a hematopoietic growth factor or colony stimulating factorand is given by injection under the skin (subcutaneous) or in the vein (intravenous). Filgrastim is approved by the U.S. Food and Drug Administration (FDA) for use in cancer patients who are at risk of developing infection due to cancer treatment. It is also approved for treating other patients who have a very low white...Drug last updated April 4, 2024.Node ID (debugging only): 4427
-
Deferoxamine is an iron-binding agent that belongs to a class of drugs known as heavy metal antagonists. It works by helping the kidneys and gallbladder get rid of the extra iron.Drug last updated April 4, 2024.Node ID (debugging only): 10502
-
The biennial Symposium will bring together physicians treating these diseases; laboratory researchers studying genetics, genomics, and pathophysiology of bone marrow failure; and clinical investigators to discuss current areas of consensus and controversy, share recent research results, and identify the highest-priority directions for basic and clinical research to advance the field. ...Webinar last updated March 21, 2024.Node ID (debugging only): 10397
-
The AAMDSIF Patient Advisory Council (PAC) was created in 2008. Its purpose is to serve as a resource to the AAMDSIF staff in the development and review of patient education materials, programs and services. Members of the PAC include doctors, nurses, patient educators, patients and caregivers, all of whom have an interest in supporting the needs of people living with aplastic anemia, MDS, PNH,...Page last updated November 13, 2023.Node ID (debugging only): 763
-
Page last updated November 13, 2023.Node ID (debugging only): 8306
-
AAMDSIF advocates for and invests in collaborative research to accelerate the discovery of better treatments and cures for bone marrow failure disorders. AAMDSIF Research Grants Since 1989, AAMDSIF has supported innovative research into the causes of bone marrow failure and the development of new therapeutic approaches. This section includes information about the grant...Page last updated November 13, 2023.Node ID (debugging only): 4404
-
Clinical trials, also called research studies, may offer good treatment options for some people with bone marrow failure diseases like aplastic anemia, MDS and PNH. This section helps you and your family understand clinical trials and gives you some things to consider when deciding whether a clinical trial is a good option for you.Sectioned page last updated October 27, 2023.Node ID (debugging only): 9848
-
Until recently, children were rarely included in studies of medical treatments. As a result, much is still unknown about how children respond to drugs, some biologics (such as gene therapy) and medical devices. According to the U.S. Food and Drug Administration (FDA), only 20-30% of approved drugs have actually been labeled for use in children. Doctors and nurses may give medicines, with doses...Sectioned page last updated October 27, 2023.Node ID (debugging only): 9863
-
Intimacy "Intimacy need not end with bone marrow failure disease. You may need to redefine your ways of expressing intimacy, and you may need to experiment because what worked before may no longer work after.” – Mayo Clinic Staff, 2003 What is the Impact of Bone Marrow Failure Disease on Sexuality and Intimacy? A medical illness can present emotional challenges concerning lifestyle,...Page last updated October 26, 2023.Node ID (debugging only): 152
-
Topic section last updated August 22, 2023.Node ID (debugging only): 4365
-
Alicia Rovó is a Senior Attending/ Deputy Phychian-in-chief and Head of the Clinial Hematology Unit at Bern University Hospital in Switzerland. Her top areas of expertise are Aplastic Anemia, Anemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.Bio last updated May 30, 2023.Node ID (debugging only): 10156
-
(excerpted from Thomas’ Hematopoietic Stem Cell Transplantation, 5th Edition) The first interface many patients have with an HCT transplant program occurs at the time they come for a second opinion. Often patients make a consultation appointment to compare a particular program with other centers they are considering. These patients meet with a transplant physician to review their options, a...Page last updated February 1, 2022.Node ID (debugging only): 2153